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Abstract
Hepatitis C virus (HCV) infection is a major cause of chronic liver disease and has become a global health threat. No HCV
vaccine is currently available and treatment with antiviral therapy is associated with adverse side effects. Moreover, there is
no preventive therapy for recurrent hepatitis C post liver transplantation. The NS3 serine protease is necessary for HCV
replication and represents a prime target for developing anti HCV therapies. Recently we described a therapeutic approach
for eradication of HCV infected cells that is based on protein delivery of two NS3 protease-activatable recombinant toxins
we named ‘‘zymoxins’’. These toxins were inactivated by fusion to rationally designed inhibitory peptides via NS3-cleavable
linkers. Once delivered to cells where NS3 protease is present, the inhibitory peptide is removed resulting in re-activation of
cytotoxic activity. The zymoxins we described suffered from two limitations: they required high levels of protease for
activation and had basal activities in the un-activated form that resulted in a narrow potential therapeutic window. Here, we
present a solution that overcame the major limitations of the ‘‘first generation zymoxins’’ by converting MazF ribonuclease,
the toxic component of the E. coli chromosomal MazEF toxin-antitoxin system, into an NS3-activated zymoxin that is
introduced to cells by means of gene delivery. We constructed an expression cassette that encodes for a single polypeptide
that incorporates both the toxin and a fragment of its potent natural antidote, MazE, linked via an NS3-cleavable linker.
While covalently paired to its inhibitor, the ribonuclease is well tolerated when expressed in naı ¨ve, healthy cells. In contrast,
activating proteolysis that is induced by even low levels of NS3, results in an eradication of NS3 expressing model cells and
HCV infected cells. Zymoxins may thus become a valuable tool in eradicating cells infected by intracellular pathogens that
express intracellular proteases.
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Introduction
Hepatitis C virus (HCV) is a small, enveloped RNA virus
belonging to the Hepacivirus genus of the Flaviviridae family. HCV
has been recognized as a major cause of chronic liver disease and
affects approximately 200 million people worldwide at the present
time. Persistent infection is associated with the development of
chronic hepatitis, cirrhosis and hepatocellular carcinoma. A
protective vaccine for HCV is not yet available and even the
most recent combination of antiviral therapy is often poorly
tolerated [1]. The HCV genome encodes one large open reading
frame that is translated as a polyprotein which is proteolytically
processed to yield the viral structural and nonstructural (NS)
proteins. The non-structural proteins include the p7 ion channel,
the NS2-3 protease, the NS3 serine protease/RNA helicase and its
co-factor NS4A, the NS4B and NS5A proteins and the NS5B
RNA-dependent RNA polymerase (RdRp) [2,3]. Two virally
encoded proteases participate in polyprotein processing, the NS2-3
autoprotease (which cleaves in cis at the NS2-3 junction) and the
NS3-4A serine protease (which cleaves at four downstream NS
protein junctions). NS3 is an extensively studied HCV protein that
possesses multiple enzymatic activities that are essential for HCV
replication, making NS3-4A the most attractive target for anti
HCV drug development [4]. The N-terminus of NS3, in complex
with its endoplasmic reticulum (ER) membrane-anchored co-
factor NS4A, primarily functions as a serine protease, which
cleaves the viral polyprotein precursor downstream to NS3. The
remaining 2/3 of the protein has a helicase and NTPase activities,
both of which are essential for HCV replication [5].
Zymogens are inactive enzyme precursors that are converted to
their active form following a biochemical modification, such as
proteolytic processing. Among the known and important groups of
enzymes that are proteolytically activated are secreted digestive
enzymes like pepsin and trypsin [6,7], the cysteine aspartic acid
proteases (caspases) which play an essential role at various stages of
the apoptotic process [8]; and blood coagulating factors [9].
Recently we described a proof of concept for potential new anti-
viral agents that can specifically eradicate virally infected cells (thus
limiting virus production and spread). These agents, which we
named ‘‘zymoxins’’ (for ‘‘zymogenized toxins’’), were composed of
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Pseudomonas exotoxin A and NS3-activable modified catalytic
domains of the bacterial or the plant toxins diphtheria toxin (DTA)
or ricin toxin (RTA), respectively. Upon binding and translocation
into cells cytoplasm by virtue of the corresponding Pseudomonas
exotoxin A domains, activation of these toxins is mediated by
HCV-NS3 protease cleavage that separates between the toxic
domains and a fused, rationally designed inhibitory peptide. These
zymoxins showed a higher level of cytotoxicity when applied to
NS3 expressing cells or to HCV infected cells, demonstrating a
potential therapeutic window. Still, the zymoxins we described had
two limitations: first, they required high levels of NS3 protease for
efficient activation, and second, they were not totally inactive in
the zymogenized state, and their basal cytotoxic activity without
proteolytic activation resulted in quite narrow therapeutic
windows [10]. Apparently, the zymoxins were only partially
inhibited by the rationally designed inhibitory peptides.
Toxic proteins that are completely inhibited by a natural
inhibitor can be found in bacterial ‘‘toxin-antitoxin’’ systems.
Natural bacterial plasmids ensure their survival within the
bacterial host by replicating inside their host cell and using
mechanisms that function to segregate them prior to cell division
[11]. In addition, several low copy number plasmids use a unique
system called ‘‘addiction module’’ or ‘‘toxin-antitoxin (TA)
system’’ which functions to prevent the proliferation of plasmid-
free cells by executing the so called ‘‘post-segregational killing
effect’’. The system consists of a pair of genes encoding for a stable
toxin and an unstable antitoxin organized in a bicistronic operon
that is transcriptionally autoregulated either by the toxin-antitoxin
complex itself or by the antitoxin alone. When coexpressed in
plasmid harboring cells, the antitoxin component interferes with
the lethal action of the toxin. If a cell loses the plasmid, the cellular
concentration of the labile antitoxin (that is degraded faster than
the more stable toxin) is rapidly diminished, enabling the toxin to
exert its action which eventually results in cell death (reviewed by
[12,13,14,15,16]). Toxin-antitoxin systems have also been found
integrated to the chromosome of various bacteria species where
their function has been the subject of considerable speculation
[14,17,18,19,20,21]. One of the most studied ‘‘genomic’’ TA
modules was found on the chromosome of E. coli as a negatively
autoregulated bicistronic operon. The system, which is activated
by several stress conditions, was denoted MazEF after its two active
protein components: the long lived MazF toxin and the labile
MazE antitoxin. MazF induced toxicity is executed by blocking de-
novo protein synthesis through its endoribonuclease activity that
catalyze the cleavage of single-stranded mRNAs at ACA sequences
[22]. When coexpressed with MazF, the MazE antitoxin
complexed with the toxin and a catalytically inactive heterohex-
amer is formed in which a MazE dimer is sandwiched between
two MazF dimers (MazF2-MazE2-MazF2) (reviewed by [21,23]).
The crystal structure of the MazE-MazF complex indicates that
the interactions between the toxin and the antitoxin are primarily
mediated by the acidic C terminus of MazE which wraps around
the MazF homodimer crossing the edge of the dimer interface
[24]. Later on, Li et al had discovered that a short acidic peptide
corresponding to MazE C-terminal 23 amino-acids, which they
denoted ‘‘MazEp’’, binds strongly to the homodimer of MazF
which possesses two identical active sites. Interestingly, it was
found that one inhibitory peptide, occupying a single active site on
the MazF homodimer, affects the conformation of both sites that
consequently become catalytically inactive. This unique mecha-
nism also explains the inhibitory activity of MazE toward MazF at
a 1:2 molar ratio [25]. The discovery of the MazF mechanism of
action was soon followed by demonstrations that it is also toxic to
eukaryotic cells, causing Bak-dependent programmed cell death in
mammalian cells, suggesting it may be used as a tool for gene
therapy against diseases such as cancer and AIDS [26,27].
Here we describe the design of a different zymoxin than those
described in [10], based on NS3-activable MazF ribonuclease that
is delivered as a transgene by an adenoviral vector. The delivered
transgene encodes for a fusion between MazF, and a potent
inhibitory peptide derived from its natural antidote MazE,
through an NS3 cleavable linker. We show that the self-inhibited,
zymogenized toxin is well tolerated when expressed in naı ¨ve cells.
In contrast, in NS3 expressing or in HCV infected cells, NS3-
mediated cleavage separates between the toxin and its inhibitor
which results in inhibition of protein synthesis followed by death of
the cells. Finally, we demonstrate that treatment with the MazF
based zymoxin has a ‘‘curing effect’’ when applied to mixed
culture of healthy and HCV infected cells, leading to specific
eradication of the infected cell population.
Results
The construction of MazF-based zymoxin
For the construction of NS3-activated MazF based zymoxin,
the MazF coding sequence was fused through its C terminus to
the HCV P10-P10’ NS3 cleavage sequence derived from the 2a
genotype (strain JFH1) NS5A/B junction. A short inhibitory
peptide corresponding to MazE C-terminal 35 amino-acids
(which encompass the 23 amino-acids inhibitory peptide (MazEp)
that has been described by Li et al. [25]) was fused, preceded by a
short flexible linker, to the C terminus of the MazF-NS3 cleavage
site sequence. A flexible linker, followed by the C-terminal ER
membrane anchor of the tyrosine phosphatase PTP1B [28], was
than fused to the C terminus of the inhibitory peptide and the
whole construct was fused through its N terminus to the
monomeric red fluorescence protein mCherry [29] (see
Figure 1). The rationale behind the design of this construct,
which was denoted ‘‘mCherry-NS3 activated MazF’’, was that
the coupling between the ribonuclease and its antidote may
enable high level of expression of the non-toxic fusion on the ER
membrane of uninfected mammalian cells without causing any
deleterious effect. In contrast, in HCV infected cells, the fusion
protein is expected to colocalize with the ER membrane-bound
viral NS3 protease (in infected cells, NS3 is localized to the
cytosolic side of the ER membrane and membranes of ER-like
modified compartments [30,31,32,33,34]). As a result, the NS3-
cleavable linker between the toxin and its inhibitory peptide is
expected to be cleaved. The toxic ribonuclease, no longer
covalently tethered to its ER membrane-anchored inhibitor, is
now free to diffuse into the cytoplasm (which lacks the antidote)
and exert its cytotoxic activity. Finally, fusion to the fluorescent
protein mCherry makes the whole construct trackable and
facilitates the determination of its expression level and intracel-
lular localization by fluorescence microscopy. As a control, an
uncleavable construct (denoted ‘‘mCherry-uncleavable MazF’’)
was constructed in which the NS3 cleavage sequence was
replaced by a mutated 14 amino acids cleavage sequence (P10-
P4’) from HCV genotype 1a NS5A/B junction in which the P3
valine was substituted by alanine, the P2 cysteine by glycine, the
P1 cysteine by glycine and the P4’ tyrosine by alanine. A
schematic representation of the NS3-activated MazF-based
zymoxin (‘‘mCherry-NS3 activated MazF’’) and the hypothetical
mechanism of its cleavage by NS3 protease on the cytoplasmic
side of the ER membrane are shown in Figure 1. The amino-
acid sequence of the MazF based zymoxins can be found in Text
S1.
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naı ¨ve cells
To verify that expression of ‘‘mCherry-NS3 activated MazF’’ is
tolerated by cells that do not express the NS3 protease, a colony
formation assay was carried out. In this assay, the toxicity of an
expressed transgene can be comparatively and qualitatively
assessed by testing its effect on the competency of transfected
cells to evolve into colonies under selection. HEK293 T-REx cells
where transfected with plasmids encoding either mCherry-NS3
activated MazF, mCherry (only the fluorescent protein) or EGFP-
MazF (where MazF is not fused to its inhibitory peptide).
48 hours (h) later, expression of the encoded transgenes was
confirmed by fluorescence microscopy (data not shown) and
transfected cells were seeded in 3 fold dilutions and were treated
with G418 (to which all three plasmids confer resistance). After 10
days of selection, surviving colonies were stained. As shown in
Figure 2, similar numbers of surviving colonies were observed
when the cells were transfected with the plasmids encoding
mCherry-NS3 activated MazF or the red fluorescent protein
alone, suggesting that expression of NS3-activable ribonuclease in
naı ¨ve HEK293 T-REx cells (that do not express NS3) cause
minimal toxicity, if any. As expected, growth was severely
inhibited when cells were transfected with the EGFP-fused active
(uninhibited) toxin.
The ER membrane-targeted zymoxin colocalizes with
NS3 protease in vivo
Previously we described a HEK293 cell line which inducibly
expresses (by addition of tetracycline) a fusion between EGFP and
the coding sequence of the full length NS3 (including the helicase
domain) followed by NS4A from HCV 1a genotype [10]. These
cells, denoted ‘‘Tet-inducible full NS3-4A expressing cells’’, were
stably transfected with a plasmid encoding the NS3-activated
zymoxin ‘‘mCherry-NS3 activated MazF’’ or with the uncleavable
control (‘‘mCherry-uncleavable MazF’’) encoding plasmid. Fol-
lowing selection, stable clones that constitutively express high level
of the cleavable construct (denoted ‘‘Tet-NS3/activated MazF
cells’’) or the uncleavable control (denoted ‘‘Tet-NS3/uncleavable
MazF cells’’) were isolated. In order to characterize the
intracellular distribution of the mCherry fused zymoxins, Tet-
NS3/activated or uncleavable MazF cells were subjected to
immunofluorescence microscopy analysis. As shown in Figure 3
(A and B), both zymoxins have a similar cellular distribution,
colocalizing with the ER marker calnexin at the juxtanuclear
region of the ER. Importantly, upon induced expression of NS3-
A4 in Tet-NS3/uncleavable MazF cells, a colocalization of the two
fluorescent fusion proteins could be observed (Figure 3, C and
D).These observations confirm that indeed both the protease and
the modified ribonuclease are tethered to a common cellular
compartment, presumably the cytoplasmic side of the ER
membrane (see scheme in Figure 1).
NS3-mediated proteolytic activation of MazF based
zymoxin inhibits de-novo cellular protein synthesis
Since expression of active MazF was found to inhibit de-novo
protein synthesis in mammalian cells [27], we hypothesized that
such an effect may be observed also in cells in which MazF based
zymoxin is proteolytically activated. In order to validate this
assumption, Tet-NS3/activated MazF and Tet-NS3/uncleavable
MazF cells were supplemented with tetracycline for 24 or 48 h,
or left untreated. Levels of de-novo protein synthesis were than
determined by [
3H]-leucine incorporation assay. As shown in
Figure 4 (upper panel), a complete shutoff in protein synthesis
was observed as soon as 24 h post NS3 induction in cells that
express the cleavable construct, indicating proteolytic activation
of the zymoxin. As expected, protein synthesis was not impaired
following NS3 induction in cells that express the uncleavable
toxin.
Figure 1. Schematic representation of the construct ‘‘mCherry-NS3 activated MazF’’ and hypothetical mechanism of activation by
NS3 protease. The NS3-activated MazF zymoxin was constructed by fusing 5 elements in the following order (from the N terminus): monomeric red
fluorescence protein mCherry, E. coli MazF ribonuclease, HCV P10-P10’ NS3 cleavage sequence derived from 2a genotype (strain JFH1) NS5A/B
junction, a short inhibitory peptide corresponding to MazE C-terminal 35 amino-acids (which encompass the 23 amino-acids inhibitory peptide
(MazEp) that has been described by Li et al. [25]) and the C-terminal ER membrane anchor of the tyrosine phosphatase PTP1B [28]. After being
anchored to the ER membrane, the NS3 cleavage site that is located between the ribonuclease and the inhibitory peptide in the ‘‘mCherry-NS3
activated MazF’’ construct (which is active as a dimer but for convenience is illustrated here in its monomeric form) is cleaved by the HCV- NS3
protease which is also localized to the cytoplasmic side of the ER membrane. The toxic ribonuclease, no longer covalently tethered to its ER-anchored
inhibitor, is now free to diffuse to the cytoplasm (which lacks the antidote) and exert its destructive activity.
doi:10.1371/journal.pone.0032320.g001
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complete cleavage of the zymoxin following tetracycline-induced
expression of NS3 protease in NS3-activated MazF expressing cells
(Figure 4, lower panel). Presumably,this proteolyticactivationof
the ribonuclease toxin resulted in a cessation of cellular protein
synthesis soon after induction, what explains the detection of
relatively low levels of NS3 protease in these cells. As expected, no
zymoxin cleavage could be detected in cells expressing the
uncleavable form of the toxin. A faint band, corresponding to a
cleaved zymoxin, can also be detected in uninduced cells that
expressthe NS3cleavableconstruct.Thiscleavagecanbeattributed
to the ‘‘leakiness’’ of the Tet inducible system, allowing a very low
Figure 2. Colony formation assay for the assessment of ‘‘mCherry-NS3 activated MazF’’ cytotoxicity toward naı ¨ve cells. A day before
transfection, 7.5610
5 HEK293 T-REx cells where seeded per well in 6 wells plate and subsequently transfected with 2 mg of plasmids encoding either
mCherry-NS3 activated MazF, mCherry (only the fluorescent protein) or EGFP- MazF (where MazF is not fused to its inhibitory peptide). 48 hours later,
transfection efficiency was assessed by fluorescence microscopy and was determined as equal between the plasmids. Transfected cells were than
trypsinized, counted and seeded in 3 fold dilutions (starting from 150,000 cells/well) in 6 well plates and were incubated for 10 days in the presence
of 1 mg/ml of G418 (to which all three plasmids confer resistance). Surviving colonies were fixed and stained with Giemsa (upper panel). Number of
surviving Colonies from wells that were seeded with 5556 cells was determined by manual counting. Each bar represents the mean 6 standard
deviation (SD) of a set of data from two wells (lower panel).
doi:10.1371/journal.pone.0032320.g002
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tetracycline. Such cleavage could not be detected in ‘‘naı ¨ve’’ cells
following transfection with NS3-cleavage substrate encoding
transgene ([10], data not shown). Apparently, this very low, basal
proteolytic activity is well tolerated by NS3 activated zymoxin
expressing cells that shows no indication of de-novo protein synthesis
inhibition in comparison to cells that express the uncleavable toxin
(see CPM values in the upper panel of Figure 4).
Figure 3. Cellular colocalization of NS3 protease and the ER-membrane targeted MazF based zymoxin. 1610
5 Tet-NS3/activated MazF
or Tet-NS3/uncleavable MazF cells were seeded on poly-L-lysine coated cover-slips in a 24 well-plate. 12 h later, the cells were supplemented with
1 mg/ml of tetracycline or left untreated. After 24 h, the cells were fixed. Uninduced Tet-NS3/activated (A) and uncleavable (B) MazF cells were
permeabilized and incubated with rabbit-polyclonal anti-calnexin antibody followed by Cy2-conjugated anti-rabbit IgG secondary antibody for ER
visualization (green). Nuclei of the uninduced cells (A and B) and induced Tet-NS3/uncleavable MaF cells (C and D) were stained by Hoechst 33258
(blue). Slides were then mounted and examined by confocal fluorescence microscope. The bar represents 20 mm.
doi:10.1371/journal.pone.0032320.g003
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protease
To evaluate the potential of the NS3-cleavable MazF based
zymoxin in eradication of NS3 expressing cells, three 96 well plates
were seeded with Tet-inducible full NS3-4A, Tet-NS3/activated
MazF or Tet-NS3/uncleavable MazF cells and were supplement-
ed with 3 fold serial dilutions of tetracycline starting with 1000 ng/
ml. After 72 h, the relative fraction of viable cells was determined
using an enzymatic MTT assay. As shown in Figure 5 (lower
panel), the expression level of NS3 can be roughly tuned by
modulation of the final tetracycline concentration in the growth
Figure 4. Inhibition of de-novo protein synthesis by NS3-activated MazF based zymoxin in NS3-expressing cells. 1610
5 Tet-NS3/
activated MazF or Tet-NS3/uncleavable MazF cells were seeded per well in 24-wells plate. 24 or 48 h later, cells were supplemented with tetracycline
to a final concentration of 1000 ng/ml, or left untreated (48 h tet, 24 h tet and no tet, respectively). 72 h after seeding, levels of de-novo protein
synthesis were determined by [
3H]-leucine incorporation assay, as described in ‘‘materials and methods’’. Results are expressed as percent of the
value obtained for cells which were not induced to express the NS3 protease (No tet). Each bar represents the mean 6 SD of a set of data determined
in triplicates. Numbers above each bar represent mean counts per minute (CPM) values for 7 micrograms total protein samples (upper panel). 30
micrograms of total protein from lysates of the described cells were analyzed by immunoblotting with mouse anti-mCherry (for detection of the
zymoxin), mouse anti-GFP (for the detection of EGFP-NS3) and mouse anti actin antibodies (loading control) followed by HRP-conjugated secondary
antibodies and ECL development. Solid arrow: full length zymoxin. Hollow arrow: N’ terminal portion of NS3-cleaved zymoxin (lower panel).
doi:10.1371/journal.pone.0032320.g004
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for induction of low NS3 expression level. Indeed, strong
cytotoxicity was clearly evident when Tet-NS3/activated MazF
cells where treated with tetracycline concentrations of down to
4 ng/ml. No cytotoxic effect was detected when the controls Tet-
NS3/uncleavable MazF or Tet-inducible full NS3-4A (protease
only) expressing cells were similarly treated (Figure 5, upper
panel). These findings demonstrate the deleterious effect of the
MazF based zymoxin specifically toward NS3 protease expressing
cells, as well as its competence to be activated by very low cellular
levels of protease. In order to obtain a visual insight at the cell
level, Tet-NS3/activated MazF and Tet-NS3/uncleavable MazF
cells were supplemented with tetracycline to a final concentration
of 10 ng/ml or 1000 ng/ml (for low and high induction levels of
NS3 expression, respectively), or left untreated. 36 h later, nuclei
were stained and cells were examined under a fluorescence
microscope. The results show that both lower and higher
induction levels of NS3 protease caused growth inhibition and
rounding of cells that constitutively expresses the cleavable MazF.
Furthermore, both green and red fluorescence were faint in these
cells, probably as a result of the destructive ribonuclease activity of
the cleaved toxin toward the NS3 protease and its own mRNA. As
expected, none of the above observations was evident when these
cells were not supplemented with tetracycline or when NS3
expression was induced to high level in cells that constitutively
express the uncleavable toxin (Figure 6).
Adenovirus-mediated delivery of mCherry-NS3 activated
MazF encoding cassette specifically eradicates NS3
expressing hepatocytes
To achieve efficient DNA delivery into mammalian cells, the
expression cassette encoding mCherry-NS3 activated MazF was
cloned into a ‘‘first generation’’ DE1/DE3 human type 5
adenoviral vector plasmid DNA by homologous recombination
in bacteria [35]. Virus particles were propagated in HEK293
packaging cells as described in the ‘‘materials and methods’’
section. In addition, a control adenoviral vector was constructed
for the delivery of a similar cassette that encodes for the
Figure 5. Eradication of NS3 expressing cells by mCherry-NS3 activated MazF. Upper panel: Tet-inducible full NS3-4A (No MazF), Tet-NS3/
activated MazF (NS3-activated MazF) or Tet-NS3/uncleavable MazF (uncleavable MazF) cells were seeded in 96 well plates (2610
4 cells per well). After
24 h, cells were supplemented with 3 fold dilutions of tetracycline starting with concentration of 1000 ng/ml, or left untreated. 72 hours later, the
fraction of viable cells (relatively to the untreated controls) was determined using an enzymatic MTT assay. Each bar represents the mean 6SD of a
set of data from six wells. Lower panel: 30 ng of total protein from lysates of Tet-NS3/uncleavable MazF cells that were supplemented with 3 fold
dilutions of tetracycline for 48 h were analyzed by immunoblotting with mouse anti-GFP (for the detection of EGFP-NS3) and mouse anti-actin
antibodies (loading control) followed by HRP-conjugated secondary antibodies and ECL development.
doi:10.1371/journal.pone.0032320.g005
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Red-fluorescent comet-like adenovirus-producing foci were ap-
parent upon infection of packaging cells with both recombinant
viruses (encoding cleavable or uncleavable constructs) (see Figure
S1). The production yields for both viruses were ,3610
8 plaque
forming units (PFU)/ml, after two ‘‘cycles’’ of virus amplification
(see Text S2).
In order to evaluate the ability of adenovirus-mediated delivery
of NS3 activated MazF encoding cassette to eradicate NS3
expressing hepatocytes, wild-type Huh7.5 hepatoma cells and our
previously described EGFP-full NS3-4A expressing Huh7.5 cells
[10] were infected with the NS3-activated or uncleavable MazF
encoding viruses. Since our previous unpublished observations and
studies of others have indicated that high level of transgene
expression and adenoviral infection, per se, may adversely affect cell
viability and growth [36,37,38,39]; the cells were infected with a
series of multiplicity of infection (MOI) ratios in order to find an
optimal MOI that leads to eradication of NS3-expressing cells
while maintaining minimal toxicity to naı ¨ve cells.
As shown in Figure 7A (left panel), infection with the NS3-
activated zymoxin resulted in a considerable cytotoxic effect
against NS3-expressing hepatocytes, leading to their almost
complete eradication at MOI’s$12. However, infection at
these ratios also adversely affected the growth of wild-type
hepatocytes. In contrast, infection at MOI of ,3d e c r e a s e dt h e
viability of the NS3-expressing Huh7.5 cells to about 35% of
the untreated control without affecting the viability of the wild-
type hepatocytes (see also microscopic examination in
Figure 7B). Therefore, infection at this MOI was applied
during the next experiments. As expected, no substantial
enhancement in cytotoxicity against NS3 expressing Huh7.5
cells (relatively to wild-type Huh7.5 cells) was observed, at any
MOI, upon infection with the uncleavable MazF encoding
viruses (Figure 7A, right panel).
Figure 6. Expression of mCherry-NS3 activated MazF results in growth inhibition and morphological changes in NS3-expressing
cells. 1610
5 Tet-NS3/activated MazF or Tet-NS3/uncleavable MazF cells were seeded on poly-L-lysine coated cover-slips in a 24 well-plate. 12 h later,
cells were supplemented with 10 ng/ml or 1000 ng/ml of tetracycline, or left untreated. 36 h later, cells were fixed. Following nuclear staining by
Hoechst 33258 (Blue), slides were examined by fluorescence microscopy. The bar represents 50 mm.
doi:10.1371/journal.pone.0032320.g006
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encoding cassette specifically eradicates HCV infected
hepatocytes
To test the competence of the MazF based zymoxin to
specifically eradicate HCV infected hepatocytes, we utilized the
infectious chimeric virus HJ3-5 [40]. This is one of the currently
used models to study hepatitis C virus in which recombinant
infectious HCV particles are produced in cell culture (HCVcc)
(for review, see [41,42]). As the main purpose of zymoxins based
treatment is the specific eradication of HCV infected cells from a
background of healthy cells, ‘‘mixed culture’’ experiments were
carried out. In these experiments, Huh7.5 hepatoma cells were
infected with the HCV 1a/2a chimeric virus HJ3-5 (encoding
the NS3 protease of genotype 2a strain JFH1 [40]). When
infection reached ,50% (about 50% of the cultured cells showed
expression of the HCV-core protein, as detected by immuno-
staining and fluorescence microscopy), the mixed culture and a
culture of uninfected cells were treated with NS3 activated MazF
or uncleavable-MazF encoding adenoviruses at MOI of ,3.
Control cells remained untreated. 72 h post adenoviral infection;
viability assay and microscopic examination that included
immunostaining for HCV-core protein were performed. As
shown, treating the mixed culture with NS3-activated MazF
zymoxin-encoding adenovirus reduced the viable cells popula-
tion to about 65% relatively to untreated control; while viability
of the uninfected cells (‘‘HCV negative’’) was barely affected by
this treatment (Figure 8, upper panel). Microscopic exami-
nation of the treated mixed culture revealed two cell populations
that differ in their appearance. While one population is
characterized by a ‘‘typical’’ Huh7.5 cell morphology (hollow
arrows, Figure 8, lower panel), the other is composed of
partially detached cells with round, condensed or distorted shape
(filled arrows) that are hypothesized to be zymoxin-intoxicated
Figure 7. Eradication of NS3-expressing Huh7.5 cells by recombinant adenovirus-mediated delivery of mCherry-NS3 activated
MazF encoding cassette. 1610
4 wild-type (W.T) or EGFP-full NS3-4A expressing Huh7.5 cells were seeded per well in 96 well plates. After 24 h,
recombinant adenoviruses encoding for mCherry-fused NS3 activated MazF or uncleavable-MazF zymoxins were added at the indicated MOI’s.
Control cells remained untreated. (A) MTT viability assay: 4 days post infection, the fraction of viable cells (relatively to uninfected controls) was
determined using an enzymatic MTT assay. A representative graph of three independent experiments is shown. Each bar represents the mean 6SD of
a set of data determined in triplicates. (B) Microscopic examination: 4 days post infection, wild-type (lower panel) or EGFP-full NS3-4A expressing
Huh7.5 cells (upper panel), uninfected or infected with recombinant adenoviruses encoding for mCherry fused NS3-activated MazF zymoxin (at MOI
of ,3), were fixed and subjected to microscopic examination. The bar represents 200 mm.
doi:10.1371/journal.pone.0032320.g007
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fraction of HCV infected cells from the general population was
evaluated by immunofluorescence analysis using anti-HCV core
protein specific antibodies. Indeed, treatment with the NS3-
activated zymoxin showed a ‘‘curing effect’’ upon the partially
infected culture, considerably reducing the fraction of the HCV
infected cells from the general population (Figure 9). As
expected, no significant effect upon the HCV infected cell
population was observed following treatment with the unclea-
vable zymoxin.
Figure 8. Treatment of HCV infected/uninfected mixed cell culture with recombinant adenovirus-delivered MazF based zymoxin.
Uninfected (HCV-negative) Huh7.5 cells and a mixed culture of HCV infected and uninfected cells at 1:1 ratio (50% infected culture) were seeded in
96-well plates (1610
4 cells/well). After 24 h, cells were treated with recombinant adenoviruses (MOI of ,3) encoding for the mCherry fused NS3-
activated MazF or uncleavable-MazF zymoxins. Control cells remained untreated. Upper panel: MTT viability assay: 72 h post treatment, the fraction
of viable cells (relatively to untreated controls) was determined using an enzymatic MTT assay. A representative graph of three independent
experiments is shown. Each bar represents the mean 6SD of a set of data determined in triplicates. Lower panel: Microscopic examination: 72 h post
treatment, the uninfected (HCV-negative) Huh7.5 cells, the mixed culture of HCV infected and uninfected cells and the control untreated cells were
fixed and subjected to microscopic examination. Hollow arrows point to cells that are characterized by a ‘‘typical’’ Huh7.5 cell morphology. Filled
arrows point to partially detached cells with round, condensed or distorted shape. The bar represents 200 mm.
doi:10.1371/journal.pone.0032320.g008
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Fight against viral infections is considered as one of the most
challenging areas in modern medicine. While vaccination is
considered to be the most efficient method for fighting viral
infections; for some viral pathogens which cause world-wide health
problem like human immunodeficiency virus (HIV) and hepatitis
C virus (HCV), no efficient vaccine has yet been developed. Over
the last years, efforts have been focused on the discovery and
development of anti-viral agents that target crucial steps in the
viral replication cycle which includes viral entry, RNA translation
and post-translational processing, reverse transcription, genome
integration, viral assembly and release [43,44,45].
An essential step in the replication cycle of many viruses is the
processing of a polyprotein precursor by a viral-encoded protease.
A partial list of human diseases associated viruses encoding
protease(s) in their genome include flaviviruses such as hepatitis C
virus (HCV), West Nile virus (WNV), dengue fever virus (DFV)
and yellow fever virus (YFV); retroviruses such as HIV-1;
picornaviruses such as coxsackievirus, poliovirus and hepatitis A
virus; nidoviruses such as coronaviruses (CoV), including the
severe acute respiratory syndrome (SARS) causative SARS-CoV
and herpesviruses such as varicella-zoster virus (VZV) and Epstein-
Bar virus (EBV) [46,47]. Therefore, a large part of antiviral drug
discovery is focused on inhibiting viral proteases [46]. Our group
too has published several studies where HCV replication was
inhibited by intracellular expression of antibodies and peptide
aptamers [48,49,50]. The opposite ‘‘side of the coin’’ – taking
advantage of the activity of a viral protease per-se as an antiviral
approach has been rather neglected.
Recently we described a study that was based on the concept of
‘‘sitoxins’’ which are anti-viral agents that are designed to
eradicate viral-infected cells by taking advantage of a specific viral
activity instead of inhibiting it [51,52]. specifically, a sitoxin is
comprised of an effector domain (e.g. a toxin); a domain bearing
an intracellular signaling moiety (e.g. a degradation or an
intracellular localization signal); and a domain located between
Figure 9. Eradication of HCV-infected hepatocytes by recombinant-adenovirus delivered MazF based zymoxin. 3610
4 cells from
mixed HCV infected and uninfected culture (at 1:1 ratio) were seeded per well into 8-well chamber slides. 24 h later, cells were treated with
recombinant adenoviruses (MOI of ,3) encoding for the mCherry fused NS3-activated MazF or uncleavable-MazF zymoxins. Control cells remained
untreated. 72 h post treatment, cells were fixed, permeabilized and immunostained with mouse anti-HCV core and FITC-conjugated goat anti mouse
antibodies for visualization of infected cells (green). Cell nuclei were then stained with DAPI (cyan) and slides were visualized by fluorescence
microscopy. The bar represents 100 mm (upper panel). The fraction (given in percentage) of HCV-infected cells from the general cell population was
evaluated, for each treatment, by dividing the number of the green, HCV-core positive cells by the general number of cells (DAPI stained) (lower
panel). Each bar represents the mean 6SD of a set of data collected from five representative microscopic fields. Numbers in brackets represent the
percentage of the HCV-infected cells in each treatment relatively to their percentage in the untreated culture.
doi:10.1371/journal.pone.0032320.g009
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signaling moiety which specifies a cleavage site for a predeter-
mined protease (e.g. a viral encoded protease). Following the
introduction of the sitoxin into the target cell (that expresses the
specific protease), cleavage by the predetermined protease
separates the toxic effector domain of the sitoxin from the
intracellular signaling moiety, resulting either in a longer-lived
(and therefore more toxic) effector domain or in an effector
domain that moves from a cellular compartment where the
domain is nontoxic to a cellular compartment where the domain is
able to exert its effect [51]. We developed and successfully
evaluated two rationally designed viral-protease-activated chimeric
toxins which we named ‘‘zymoxins’’ for ‘‘zymogenized toxins’’
[10]. In contrast to sitoxins, in which the inhibitory activity is
mediated by intracellular components which recognize a cleavable
signaling polypeptide fused to a constitutively active toxin; the
concept of zymoxins is based on the idea of reengineering a toxic
enzyme into an inactive zymogen which is specifically activated by
a predetermined protease. This general approach was demon-
strated by other elegant studies in which several enzymes,
including bovine RNase A, Vip2 and the maize ribosome
inactivating protein (maize-RIP) were converted into protease
activated forms [53,54,55,56,57].
Our previous work focused on the design of protein-delivered
toxins that were converted into protease-activated forms by means
of fusion to specific, rationally designed inhibitory peptides
through HCV-NS3 protease cleavable linker. When tested in-vitro
and on NS3-overexpressing or HCV infected cells, a clear NS3
protease cleavage-dependent enhancement in activity/cytotoxicity
was observed. However, these constructs had two major
drawbacks, as mentioned in the introduction: The first is the
incomplete inhibition of the toxic enzymatic activity that is
conferred by the rationally designed fused peptide. The second
relates to the necessity of relatively high level of expressed viral
protease for achieving adequate zymoxin activation inside the cells
[10].
In the current study, we turned to evaluate a similar strategy for
eradicating HCV-infected cells, namely, by converting a consti-
tutively active enzyme into an NS3 activated zymogen. As a toxic
moiety, we chose MazF, an endoribonuclease that together with its
polypeptidic antidote, MazE, constitute one of the most studied
‘‘genomic’’ toxin-antitoxin systems in E. coli. In order to convert
MazF into a zymoxin, a fusion polypeptide was constructed in
which an inhibitory peptide derived from the MazE antitoxin was
fused to the C terminus of the MazF toxin via an NS3-cleavable
linker. Regarding the issue of incomplete inhibition of zymoxin’s
activity in uncleaved form, it should be mentioned that in contrast
to our previously described constructs, in which a ‘‘rationally
designed’’ peptide is appended to provide the inhibition of the
toxin’s activity; in the MazF based-zymoxin, a ‘‘natural’’ inhibitory
polypeptide was chosen for that purpose. Antidote polypeptides in
toxin-antitoxin systems were ‘‘evolutionary shaped’’ to strongly
inhibit the destructive activity of their toxic counterparts. Thus, a
very efficient inhibition may be achieved when using them as
inhibitory peptides in the construction of zymoxins. Indeed, our
results show that the fused MazE-derived inhibitory peptide
diminishes the toxin’s activity to such an extent that enables its
non-lethal overexpression in naı ¨ve cells.
In order to improve the responsiveness of the zymoxin to the
presence of low levels of cellular-expressed viral protease, an ER
membrane ‘‘anchoring peptide’’ was fused to the C terminus of the
construct, subsequently to the MazE derived inhibitory peptide.
By using that design, a colocalization between the ER-bound NS3
protease and its zymoxin substrate might be achieved, resulting in
an improved cleavage efficiency. Indeed, such a colocalization
could be observed, as shown above (Figure 3). Moreover,
activation of the zymoxin was evident also upon expression of
very low cellular levels of the viral protease (Figures 5 and 6).
It should also be mentioned that while being extremely sensitive
to minute amounts of expressed NS3 protease, zymoxin expressing
cells can still tolerate some degree of activating proteolysis (as
shown above for NS3-activated MazF expressing cells that show a
very low, basal NS3 proteolytic activity without tetracycline
induction (Figure 4)). This property may, in fact, contribute to the
specificity and general safety of zymoxin-based therapeutics, even
though ‘‘spontaneous’’, unspecific proteolytic activity toward NS3
substrates could not be detected in naı ¨ve cells during our
experiments (data not shown). As discussed, tethering the zymoxin
to the ER membrane through its inhibitory peptide may also
enhance its cleavage-dependent toxicity. This might be achieved
by enabling spatial separation between the activated toxin and its
antidote following NS3-cleavage and diffusion of the active MazF
to the inhibitory peptide-free cytoplasm. Supporting this assump-
tion, we found that although cleaved, a cytoplasmic version of the
NS3-activated MazF based zymoxin is barely toxic to NS3
protease-expressing cells (data not shown).
In contrast to our previous study, in which the toxins were
delivered into mammalian cells as purified recombinant proteins;
in the current research an adenoviral vector gene-delivery system
was used. Widely applied in gene therapy, recombinant viral
vaccines and basic science studies, this system enables efficient
delivery and high level of transgene expression in a wide variety of
human cells. Using this system, we have demonstrated specific
eradication of full NS3-4A expressing Huh7.5 cells, sparing
‘‘naı ¨ve’’ cells which do not express the protease. Furthermore,
specific eradication of HCV infected cells has also been achieved,
demonstrating a prominent ‘‘curing effect’’ when tested on mixed
cultures of healthy and HCV infected hepatocytes.
The use of viral gene delivery for treating HCV infection by
eradication of infected cells has been proved successful in previous
study on mice with chimeric human livers. In that study, Hsu et al
designed a modified proapoptotic BID molecule in which its
endogenous cleavage sites were replaced by NS3 recognition site.
As BID requires proteolytic processing in order to activate its
apoptotic function, infection with adenoviral vector that delivers a
transgene encoding the engineered BID molecule was demon-
strated to induce activation of apoptosis in cells expressing the
HCV NS3 protease. Moreover, a significant reduction in HCV
titer in the serum of the HCV infected mice was detected following
injection of the engineered adenoviral vector into the jugular vein
[58].
Although such an approach had proved successful; it should be
taken into account that a delivered transgene which encodes for a
modified form of a protein that is naturally expressed in the target
cell has the potential to negatively influence normal cellular
processes in which its endogenous counterpart plays a role
[59,60,61,62,63]. For example, when overexpressed in non-
infected cells, an NS3-cleavable apoptotic molecule, such as that
described above, may act as a ‘‘dominant negative’’ by competing
with the natural, endogenous protein for interactions with
activators, regulators or substrates. Delivery of a transgene
encoding for a foreign protein which has no endogenous
counterpart in target cells, such as MazF, may reduce that risk.
Furthermore, it should be noted that MazF possess a ribonuclease
activity that is also capable of processing multiple potential
cleavage sites in the HCV genome. Although not evaluated in this
study, a direct attack on the parasite’s genetic material may
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parallel with host-cell protein synthesis shutoff.
Of note, the applicability of the described zymoxin may be
extended by replacing the protease cleavage site that separates
between the toxic moiety and the inhibitory peptide. This could
facilitate eradication of cells that are infected with other protease
expressing viruses other than HCV (a partial list of protease
expressing viruses is given at the beginning of the discussion) or
different strains of HCV that differ in their NS3 protease cleavage
specificity. In addition, one may replace the C terminal ER
anchoring peptide with sequence that tethers the construct to a
different intracellular location in which the viral protease resides.
In that way, a colocalization between the zymoxin and the
predetermined viral protease may be achieved.
In conclusion, the presented anti-viral agent was designed
following our previously described ‘‘zymoxins’’ concept in which a
constitutively active toxin is converted into a ‘‘zymogenized’’,
viral-protease activated from. The MazF-based zymoxin, that is
introduced to target cells by means of adenovirus mediated gene
delivery, shows very low toxicity to naı ¨ve cells and enhanced
responsiveness to low viral-protease expression level, when
compared to our previously presented constructs. As evident from
our results, the MazF based zymoxin eradicates NS3-expressing
model cells and HCV infected cells with remarkable efficiency and
specificity, providing further proof to the concept of zymoxins and
a potential new means of fighting viral diseases. Obviously, further
optimizations and pharmacological assessments in animal models
may be required in order to determine the safety and efficiency of
zymoxins treatment in the context of the whole organism.
Materials and Methods
Bacterial strains
The following Escherichia coli (E. coli) strains were used: XL-1
Blue and DH5a (Stratagene, USA) for plasmid propagation and
BJ5183 (Stratagene, USA) for the generation of recombinant
adenovirus plasmid DNA.
Recombinant DNA techniques and vectors
Recombinant DNA techniques were carried out according to
standard protocols or as recommended by the suppliers.
Nucleotide sequences were determined using the PRISM 3100
Genetic Analyzer (Applied Biosystems, USA) according to the
supplier’s recommendations. The eukaryotic CMV promoter-
based GFP-fusion expression vector pEGFP C2, which was used
for expression of mCherry, MazF and MazF-based zymoxins, was
from Clontech (USA). The AdEasy plasmid system (pShuttle and
pAdEasy-1) [35], that was used for generation of recombinant
human type 5 adenoviral vectors for gene delivery of the zymoxins
expression cassettes, was a generous gift from Prof. Nadir Arber,
Integrated Cancer Prevention Center, Tel Aviv Sourasky Medical
Center, Israel. All plasmid and DNA fragment purifications were
carried out with High-Speed Plasmid Mini Kit and Gel/PCR
DNA fragments Extraction Kit (Geneaid Biotech Ltd., Taiwan)
unless mentioned otherwise. T4 DNA ligase and restriction
enzymes were purchased from New England Biolabs (USA).
DNA ligations were carried out at 16uC overnight.
Molecular cloning
Oligonucleotides. All the oligonucleotides that were used in
this study were purchased from Hylabs, Israel. Oligonucleotides
that were used in this study are listed in Table S1.
Construction of the vector encoding for ‘‘mCherry-NS3
activated MazF’’. A polymerase chain reaction (PCR) was
carried out using a single colony of Escherichia coli strain XL-1 as a
template, the forward primer: 40- clvmazf and the reverse primers:
41-clvmazf, 42-clvmazf, 43-clvmazf, 44-clvmazf, 45-clvmazf, 46-
clvmazf and 47-clvmazf. The PCR product, encoding for a fusion
polypeptide composed of (from the N terminus) MazF, HCV P10-
P10’ NS3 cleavage sequence derived from 2a genotype (strain
JFH1) NS5A/B junction, a short flexible linker, a short inhibitory
peptide corresponding to MazE C-terminal 35 amino-acids (which
encompass the 23 amino-acids inhibitory peptide (MazEp) that has
been described by Li et al. [25]), a flexible linker and the C-
terminal ER membrane anchor of the tyrosine phosphatase
PTP1B [28] was digested with XhoI and EcoRI and was cloned
between the corresponding sites in the plasmid pEGFP-C2,
generating plasmid ‘‘pEGFP-NS3 activated MazF’’. Next, the
sequence of the red fluorescent protein mCherry [29] was
amplified by PCR from an expression cassette (kindly provided
by Prof. Adi Avni, Department of Molecular Biology and Ecology
of Plants, Tel-Aviv university, Israel) using the forward primer: 48-
clvmazf and the reverse primer: 49- clvmazf. The PCR product
was digested with NheI and XhoI and was cloned between the
corresponding sites of the plasmid ‘‘pEGFP-NS3 activated MazF’’
(replacing the EGFP coding sequence), generating plasmid:
‘‘pmCherry-NS3 activated MazF’’. The amino-acid sequence of
the encoded cleavable zymoxin can be found in Text S1.
Construction of the vector encoding for ‘‘mCherry-
uncleavable MazF’’. A PCR was carried out using DNA of
plasmid ‘‘pmCherry-NS3 activated MazF’’ as a template, the
forward primer: 40- clvmazf and the reverse primers: 50-unclmazf
and 51-unclmazf. The PCR product was digested with EcoRV and
NruI, and the digestion product of 233 bp was cloned between the
corresponding sites of the same plasmid that has been used as a
template, generating the plasmid: ‘‘pmCherry–uncleavable
MazF’’. This plasmid encodes for an uncleavable construct in
which the NS3 cleavage sequence was replaced by a mutated 14
amino acids cleavage sequence (P10-P4’) from HCV genotype 1a
NS5A/B junction in which P3 valine was substituted by alanine,
P2 cysteine by glycine, P1 cysteine by glycine and P4’ tyrosine by
alanine. The amino-acid sequence of the encoded uncleavable
zymoxin can be found in Text S1.
Construction of the vector encoding for ‘‘EGFP-
MazF’’. This is a mutated variant of an ‘‘intermediate’’ vector
used in the construction process of the ‘‘mCherry-NS3 activated
MazF’’ encoding vector. In this variant, a nonsense mutation was
inserted instead of the tyrosine in the SMSY sequence of the NS3
recognition site, generating the plasmid ‘‘pEGFP-MazF’’ that
encodes for a truncated EGFP-MazF fusion protein that lacks the
MazE derived inhibitory peptide and the ER anchor.
Construction of the vector encoding for mCherry. The
sequence of the red fluorescent protein mCherry [29] was
amplified by PCR from an expression cassette (see construction
of the vector encoding for ‘‘mCherry-NS3 activated MazF’’) using
the forward primer: 48- clvmazf and the reverse primer: 49-
clvmazf. The PCR product was digested with NheI and BglII and
was cloned between the corresponding sites of the plasmid pEGFP
C2 (replacing the EGFP coding sequence), generating the plasmid
‘‘pmCherry’’.
Construction and propagation of recombinant adenoviral
vectors. Construction and propagation of recombinant human
type 5 adenoviral vectors for gene delivery of the mCherry-NS3
activated MazF and mCherry-uncleavable MazF expression
cassettes was carried out using the AdEasy system essentially as
described in [35,64]. A more detailed description of the procedure
is provided in Text S2.
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immunoblotting
Human embryonic kidney cells HEK293, stably expressing the
tetracycline repressor protein (T-REx HEK293 Cell Line,
Invitrogen, USA), and human hepatoma cells Huh7.5 [65] were
used throughout this study. Cell lines were maintained in
Dulbecco’s Modified Eagle Medium (DMEM) supplemented with
10% fetal calf serum (FCS), 2 mM L-glutamine, 100 U/ml
penicillin and 100 mg/ml streptomycin (Biological Industries,
Israel) in a humidified 5% CO2 incubator at 37uC.
The calcium-phosphate transfection method was applied for
introducing 2 mg of the plasmid ‘‘pmCherry-NS3 activated MazF’’
or the plasmid ‘‘pmCherry-uncleavable MazF’’ into T-REx
HEK293 cells inducibly expressing EGFP-Full NS3-4A [10] seeded
1.5610
6 cells per 60 mm plate 24 h before transfection. Stable
transfectants, inducibly expressing EGFP-Full NS3-4A and consti-
tutively expressing mCherry-NS3 activated MazF (denoted ‘‘Tet-
NS3/activated MazF cells’’) or mCherry-uncleavable MazF (denot-
ed ‘‘Tet-NS3/uncleavable MazF cells’’) were selected in a medium
containing 1 mg/ml of G418 (A.G. Scientific, USA). Cellclones that
express high level of the cleavable construct or the uncleavable
control were identified by fluorescence microscopy and isolated.
For protein extraction, 48 h post-transfection the cells were
washed with PBS, scraped and lysed in a buffer containing 150 mM
NaCl, 5 mM EDTA, 0.5% NP-40, 10 mM Tris(HCl) pH 7.5, and
protease inhibitors cocktail (Sigma, Israel). Following 30 minutes of
incubation on ice, lysates were cleared by centrifugation at 20,000 g
for 10 minutes, at 4uC. For immunoblotting, protein samples were
electrophoresed on 12% SDS/polyacrylamide gel, transferred to
nitrocellulose and detected using mouse monoclonal anti-mCherry
antibody (Clontech, USA), mouse monoclonal anti-GFP antibody
(Santa-Cruz, USA) or mouse monoclonal anti-actin antibody
(Abcam, USA), followed by horseradish peroxidase (HRP)-conju-
gated goat anti-mouse antibodies (Jackson ImmunoResearch
Laboratories, USA) and enhanced chemiluminescence (ECL)
detectionusingSuperSignalWestPicoChemiluminescentSubstrate
(Thermo SCIENTIFIC/Pierce, USA).
HCV infection
Virus assays were carried out with an inter-genotypic chimeric
hepatitis C virus (HCV) produced by replacing the core-NS2
segment of the JFH-1 virus genome with the comparable segment of
the genotype 1a H77 virus. This chimeric virus, HJ3-5 (Kindly
provided by Prof. Stanley Lemon, University of Texas at
Galveston), contains two compensatory mutations that promote its
growth in cell culture as described previously [40]. HCV RNAs
were transcribed in vitro and electroporated into cells essentially as
described previously [66,67]. In brief, 10 mgo fin vitro-synthesized
HCV RNA was mixed with 5610
6 Huh7.5 cells in a 2-mm cuvette
and pulsed twice at 1.4 kV and 25 mF. Cells were seeded into 12-
well plates or 25-cm
2 flasks, and passaged at 3-to 4-day intervals
posttransfection by trypsinization and reseeding with a 1:3 to 1:4
split into fresh culture vessels. When infectivity reached ,50%, as
was monitored by immunofluorescent staining with anti HCV core
protein mouse monoclonal antibody (Affinity BioReagents, USA)
and Cy2-conjugated goat anti-mouse IgG (Jackson ImmunoRe-
search Laboratories, USA) (see ‘‘visualizing HCV infected cells
(infectivity assay)’’ below), the mixed culture (of uninfected and
HCV infected cells in 1:1 ratio) was taken for cytotoxicity assays.
Fluorescence/Immunofluorescence Microscopy
Confocal fluorescence microscopy analysis of T-REx
HEK293 cells inducibly expressing EGFP-full NS3-4A and
constitutively expressing mCherry-NS3 activated or
uncleavable MazF. 1610
5 Tet-NS3/activated MazF or Tet-
NS3/uncleavable MazF cells were seeded on poly-L-lysine coated
cover-slips in a 24 well-plate. 12 h later, the cells were
supplemented with 1 mg/ml of tetracycline, or left untreated.
24 h later, the cells were fixed with 4% formaldehyde in PBS.
Uninduced cells were permeabilized with Triton X-100 (0.1%
in PBS) for 5 minutes, blocked with 90% fetal calf serum/10%
PBS at room temperature for 25 minutes, incubated with 1:200
diluted rabbit-polyclonal anti-calnexin antibody (Sigma, USA) as
primary antibody for 1 h and followed by 1:200 diluted Cy2-
conjugated anti-rabbit IgG (Jackson ImmunoResearch Laborato-
ries, USA) secondary antibody for 30 minutes. Nuclei of induced
and uninduced cells were then stained by Hoechst 33258 for 1 h at
room temperature. Slides were washed with PBS, mounted in
Mowiol 4-88 solution (Calbiochem, USA) (immunostained unin-
duced cells) or ImmuGlo Mounting Medium (IMMCO Diagnos-
tics, USA) (induced Tet-NS3/uncleavable MazF cells) and
examined using a Zeiss LSM 510 META laser scanning confocal
microscope.
Visualizing T-REx HEK293 cells inducibly expressing
EGFP-full NS3-4A (supplemented with different tetracycline
concentrations) and constitutively expressing mCherry-NS3
activated MazF or mCherry-uncleavable MazF. 1610
5 Tet-
NS3/activated MazF or Tet-NS3/uncleavable MazF cells were
seeded on poly-L-lysine coated cover-slips in a 24 well-plate. 12 h
later, cells were supplemented with 10 ng/ml or 1000 ng/ml of
tetracycline, or left untreated. 36 h later, cells were fixed with 4%
formaldehyde in PBS. Following nuclear staining by Hoechst 33258
for 1 h at room temperature, Slides were washed with PBS,
mounted in ImmuGlo Mounting Medium and examined using a
fluorescence microscope.
Visualizing HEK293 cells infected with recombinant
adenovirus encoding for mCherry-NS3 activated MazF or
mCherry-uncleavable MazF. 3610
5 HEK293 cells were
seeded per well in 6 wells plate. When the culture reached 90%
confluence, the growth medium was replaced by fresh medium
containing 10 fold dilutions of recombinant adenoviruses encoding
for mCherry-NS3 activated MazF or mCherry-uncleavable MazF,
starting from 2.5610
6 PFU per well. After 36 h, cells were fixed
with 4% formaldehyde in PBS and examined using a fluorescence
microscope.
Visualizing HCV infected cells (infectivity assay). Huh7.5
cells infected with HCV HJ3-5 chimeric virus were seeded into 8-
well chamber slides (Nalge Nunc, USA). After 24 h, cells were fixed
and permeabilized with 1:1 acetone/methanol mixture and stained
with 1:300 diluted mouse monoclonal antibody C7-50 (Affinity
BioReagents, USA) specific for the HCV core protein followed by
staining with 1:100 diluted Cy2-conjugated goat anti-mouse IgG
(Jackson ImmunoResearch Laboratories, USA). Nuclei were then
stained with DAPI (Sigma, Israel) and slides were washed with PBS,
mounted (SouthernBiotech, USA) and examined using a
fluorescence microscope.
Visualizing zymoxin-treated mixed culture of uninfected
andHCVinfectedcells. See‘‘Cytotoxicityassayofrecombinant
adenoviruses encoding for mCherry-NS3 activated MazF or
mCherry-uncleavable MazF on a mixed culture of uninfected and
HCV-infected Huh7.5 cells’’ below.
Colony formation assay
7.5610
5 HEK293 T-REx cells were seeded per well in 6 wells
plate. 24 h later, cells were transfected with 2 mg of the plasmids
‘‘pmCherry-NS3 activated MazF’’, ‘‘pmCherry’’ or ‘‘pEGFP-
MazF’’ encoding for mCherry-NS3 activated MazF, mCherry
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fused to its inhibitory peptide), respectively. Transfection was
carried out using FuGENE 6 reagent (Roche, Germany) according
to the manufacturer instructions. After 48 h, transfection efficiency
was assessed by fluorescence microscopy and was determined as
equal between the plasmids. Transfected cells were then
trypsinized, counted and seeded in 3 fold dilutions (starting from
150,000 cells/well) in 6 well plates and were incubated for 10 days
in the presence of 1 mg/ml of G418 (to which all the three
plasmids confer resistance). Surviving colonies were fixed with 4%
formaldehyde in PBS and stained with Giemsa (Sigma, USA).
Number of surviving colonies from wells that were seeded with
5556 cells was determined by manual counting.
Cell-viability assay
The cell-killing activities of NS3-activated MazF and unclea-
vable MazF zymoxins were measured by a Thiazolyl Blue
Tetrazoliam Bromide (MTT) assay as described below:
Cytotoxicity assay of intracellularly expressed mCherry-
NS3 activated MazF or mCherry-uncleavable MazF in T-
REx HEK293 cells inducibly expressing EGFP-Full NS3-
4A. Tet-inducible full NS3-4A, Tet-NS3/activated MazF or
Tet-NS3/uncleavable MazF cells were seeded in 96 well plates
(2610
4 cells per well). After 24 h, cells were supplemented with 3
fold dilutions of tetracycline starting with concentration of
1000 ng/ml, or left untreated. 72 h later, the media was
replaced by fresh media (100 ml per well) containing 1 mg/ml
MTT (Thiazolyl Blue Tetrazoliam Bromide (Sigma, Israel)
dissolved in PBS) reagent and the cells were incubated for
further 30 minutes. MTT-formazan crystals were dissolved by the
addition of extraction solution (20% SDS, 50% N, N-Dimethyl
Formamide (DMF), pH 4.7) (100 ml per well) and incubation for
16 h at 37uC. Absorbance at 570 nm was recorded on an
automated microtiter plate reader. The results were expressed as
percentage of living cells relatively to the untreated controls.
Cytotoxicity assay of recombinant adenoviruses encoding
for mCherry-NS3 activated MazF or mCherry-uncleavable
MazF on full NS3-4A expressing Huh7.5 cells. 1610
4 wild-
type or EGFP-full NS3-4A expressing Huh7.5 cells [10] were seeded
per well in 96 well plates. After 24 h, growth media were replaced by
fresh media containing recombinant adenoviruses encoding for
mCherry-NS3 activated MazF or mCherry-uncleavable MazF at
indicated multiplicity of infection (MOI) ratios. Control cells
remained untreated. Four days post infection, the media was
replaced by fresh media (100 ml per well) containing 1 mg/ml
MTT (except in representative wells in which cells were fixed and
microscopically examined) and the cells were incubated for further
60 minutes. The next steps were identical to theses described above.
Cytotoxicity assay of recombinant adenoviruses encoding
for mCherry-NS3 activated MazF or mCherry-uncleavable
MazF on a mixed culture of uninfected and HCV-infected
Huh7.5 cells. Uninfected Huh7.5 cells and mixed culture of HCV
infected and uninfected cells at 1:1 ratio (50% infected culture) were
seeded in 96-well plates (1610
4 cells/well). After 24 h, cells were
treated with recombinant adenoviruses (at MOI of ,3) encoding for
mCherry-NS3 activated MazF or mCherry-uncleavable MazF
zymoxins. Control cells remained untreated. 72 h later, the media
was replaced by fresh media (100 mlp e rw e l l )c o n t a i n i n g1m g / m l
MTT (except in representative wells in which cells were fixed and
microscopically examined) and the cells were incubated for further
60 minutes. The next steps were identical to these described above.
For HCV-infection immunofluorescence analysis, 3610
4 cells
from the HCV infected and uninfected mixed culture were seeded
per well into 8-well chamber slides (Nalge Nunc, USA). 24 h later,
cells were treated with recombinant adenoviruses (MOI of ,3)
encoding for the mCherry-NS3 activated MazF or mCherry-
uncleavable MazF zymoxins. Control cells were remained
untreated. 72 h post treatment, cells were fixed and permeabilized
with 1:1 acetone/methanol mixture and stained with 1:300 diluted
mouse monoclonal antibody C7-50 (Affinity BioReagents, USA)
specific for the HCV core protein followed by staining with 1:100
diluted FITC-conjugated goat anti-mouse IgG (Jackson Immu-
noResearch Laboratories, USA). Nuclei were then stained with
DAPI and slides were mounted (SouthernBiotech, USA) and
examined using a fluorescence microscope. For each treatment,
evaluation of the fraction of the HCV-infected cells from the
general cell population was performed by dividing the number of
the green, HCV-core positive cells by the general number of cells
(DAPI stained) from five representative microscopic fields.
[
3H]-leucine incorporation assay
1610
5 Tet-NS3/activated MazF or Tet-NS3/uncleavable
MazF cells were seeded per well in 24-wells plate. 24 or 48 h
later, cells were supplemented with tetracycline to a final
concentration of 1000 ng/ml, or left untreated. 72 h after seeding,
cells were supplemented with [
3H]-leucine (Perkin Elmer, USA) to
a final concentration of 1 mCi/ml and returned to incubation.
After 6 h, cells were scraped, washed with PBS and lysed by four
freeze/thaw cycles. 7 mg total protein form the lysate of each
treatment were then add to a solution containing PBS and a final
concentration of 150 mg bovine serum albumin (BSA) in a total
volume of 75 ml. The solution was then mixed with an identical
volume of ice-cold 10% trichloro acetic acid (TCA). Mixtures were
then incubated on ice for 30 minutes and centrifuged for
10 minutes at 20,000 g, 4uC, after which the pellet was washed
with ice-cold 5% TCA, followed by washing with ice-cold 80%
ethanol. The pellet was then dissolved in 300 ml of 0.1 M NaOH,
transferred to a scintillation tube and neutralized with 200 ml1M
HCl. 4 ml of scintillation liquid was added and radioactivity was
counted by a beta-counter device.
Supporting Information
Figure S1 Fluorescence microscopy analysis of adeno-
virus producing foci. 3610
5 HEK293 cells were seeded per
well in 6 wells plate. When reached 90% confluence, cells were
infected with 10 fold dilutions of recombinant adenoviruses
encoding for mCherry-NS3 activated MazF or mCherry-unclea-
vable MazF, starting from 2.5610
6 PFU per well. After 36 h, cells
were fixed and examined under a fluorescence microscope. Red
fluorescent adenovirus-producing foci from wells infected with
2.5610
3 PFU are shown. The bar represents 200 mm.
(DOC)
Table S1 Oligonucleotides that have been used in this
study.
(DOC)
Text S1 Amino-acid sequences of MazF based zymox-
ins.
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Text S2 Construction and propagation of recombinant
adenoviral vectors.
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